Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints Overall safety consistent with sovleplenib known profile .
Pharmacogenomics is gaining support in mental health and polypharmacy, where the data make a strong case for improvements in clinical and economic outcomes.